Recent News

• 08.05.2026 - Glucotrack Announces $5.5 Million Financing
• 07.31.2026 - Lōkahi Therapeutics™ ai² Futures Lab™ Changes How Biopharma Builds a Pipeline
• 07.29.2026 - Lōkahi Therapeutics™ Advances LT-100 Development Strategy Toward Single-Injection Administration
• 07.16.2026 - UPDATE – Glucotrack and Lōkahi Therapeutics Complete Strategic Business Combination, Establishing Lōkahi-Controlled Public Platform
• 07.14.2026 - Glucotrack and Lōkahi Therapeutics Complete Strategic Business Combination, Establishing Lōkahi-Controlled Public Platform
• 07.08.2026 - Glucotrack Announces USPTO Notice of Allowance for Patent Application Covering Its Implantable CBGM Platform
• 02.04.2025 - Glucotrack, Inc. Announces Pricing Of $3.0 Million Public Offering
• 02.04.2025 - Glucotrack Announces Successful Completion Of Its First Human Clinical Study Of Continuous Blood Glucose Monitor
• 01.30.2025 - Glucotrack Announces Reverse Stock Split
• 01.30.2025 - Glucotrack Announces Reverse Stock Split

Recent Filings

• 08.05.2026 - 8-K Current report
• 08.05.2026 - EX-99.1 EX-99.1
• 07.31.2026 - PRE 14A Other preliminary proxy statements
• 07.30.2026 - 8-K Current report
• 07.30.2026 - EX-99.1 EX-99.1
• 07.29.2026 - 8-K/A Current report
• 07.27.2026 - 8-K Current report
• 07.17.2026 - ARS Annual Report to Security Holders
• 07.17.2026 - DEF 14A Other definitive proxy statements
• 07.15.2026 - 425 Prospectuses and communications, business combinations